Researchers at UCLA have identified a method that could overcome a critical limitation in cancer immunotherapy by preventing immune cells from becoming exhausted in the tumor environment. Many immunotherapies fail because CAR-T cells become starved of oxygen within tumors, losing their effectiveness against both solid and non-solid tumors. The new preclinical study demonstrates a way to deliver needed glucose to these fighter immune cells while preventing tumor cells from hijacking the energy supply.
This approach involves tweaking the metabolic pathways that deliver energy to immune cells, keeping them active and lethal to cancer cells. The research offers hope for improving existing immunotherapies that often fail when immune cells become exhausted in the challenging tumor microenvironment. The findings could provide valuable insights to biotechnology companies working in this field, including enterprises like Calidi Biotherapeutics Inc. that are developing advanced cancer treatments.
The significance of this research lies in addressing what has been a fundamental barrier to effective cancer immunotherapy. While CAR-T cell therapies have shown remarkable success against some blood cancers, they have been less effective against solid tumors partly because of the hostile tumor microenvironment that starves immune cells of necessary resources. By ensuring immune cells maintain their energy supply, this method could potentially expand the effectiveness of immunotherapies to more cancer types.
This research was reported through specialized communications platform BioMedWire, which focuses on developments in biotechnology, biomedical sciences and life sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio at IBN that provides distribution to thousands of news outlets and reaches millions through various channels. The platform serves both private and public companies seeking to communicate scientific advancements to investors, journalists, and the general public.
The implications of this research extend beyond academic circles to practical applications in cancer treatment development. As immunotherapy continues to revolutionize cancer care, methods to enhance the persistence and effectiveness of engineered immune cells could significantly improve patient outcomes. The metabolic approach identified by UCLA researchers represents a promising direction for overcoming one of the most persistent challenges in making immunotherapy effective against a broader range of cancers.
